FMC Corporation Reports Mixed Q1 2026 Results, Reaffirms Full-Year Outlook Amid Strategic Review
Event summary
- FMC Corporation reported Q1 2026 revenue of $759 million, down 4% year-over-year, with Adjusted EBITDA of $72 million, a 40% decline from Q1 2025.
- The company maintained its full-year 2026 outlook, expecting revenue between $3.60 billion and $3.80 billion, a 5% decline at the midpoint.
- FMC is exploring strategic alternatives, including potential divestitures, while advancing operational priorities such as debt reduction and portfolio optimization.
- Organic revenue declined 9% in Q1 2026, driven by lower pricing and unfavorable costs, including tariffs and raw material costs.
- The company reported a GAAP net loss of $281 million in Q1 2026, primarily due to tax charges, restructuring costs, and higher interest expenses.
The big picture
FMC Corporation's Q1 2026 results reflect the challenges of managing a post-patent transition for key products like Rynaxypyr®, along with broader market pressures. The company's strategic review and operational priorities aim to address these issues, but the path forward will depend on its ability to navigate competitive dynamics and execute on its financial targets. The agricultural sciences sector continues to face pressures from pricing competition and regulatory environments, making strategic agility crucial for players like FMC.
What we're watching
- Strategic Alternatives
- The progress and potential outcomes of FMC's evaluation of strategic alternatives, including divestitures or other transactions, will be critical to watch.
- Operational Priorities
- The company's ability to execute on its operational priorities, such as debt reduction and portfolio optimization, will impact its financial health and strategic positioning.
- Market Conditions
- The impact of competitive market conditions, particularly in Latin America, and the company's ability to manage pricing and volume dynamics will be key factors to monitor.